Skip to main content
Premium Trial:

Request an Annual Quote

Danaher Prices €1.7 Billion Offering of Senior Notes

NEW YORK – Danaher announced Wednesday that it has priced its offering of €1.7 billion ($1.9 billion) senior notes.

The offering consists of €750 million principal amount of 1.7 percent senior notes due 2024; €500 million principal amount of 2.1 percent senior notes due 2026; and €500 million principal amount of 2.5 percent senior notes due 2030.

The Washington, DC-based conglomerate said it expects to use the funds for general corporate purposes, potentially including repaying some of its outstanding commercial paper borrowings or repayment of amounts borrowed under its five-year revolving credit facility. 

The offering is expected to close March 30.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.